Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Inclusion Criteria

• •For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
• •Histologically confirmed diagnosis of Classical Hodgkin Lymphoma (cHL)
• •Patients who are treatment-naïve, or are within ± 2 weeks beginning any line of therapy at time of enrollment
• •Patients must be within ± 2 weeks of Day 1 of the first cycle of any line of therapy to enroll; a cycle is practice-defined for chemotherapy, targeted therapy, or immunotherapy-based regimens.
• •Any Eastern Cooperative Oncology Group (ECOG) or Karnofsky performance status (PS)
• •Patients must have available medical records for the date of diagnosis of cHL and available medical records documenting any prior treatment and treatment dates for the Hodgkin lymphoma, including chemotherapy, radiation, surgery and other anti-cancer therapy received.
• •Patients must consent for use of their FFPE tissue blocks for exploratory analyses